球孢子菌病市场按药物类别、感染类型、细菌种类、给药途径、分销管道、最终用户和患者类型划分 - 2025-2032 年全球预测

预计到 2032 年，球孢子菌病市场规模将成长至 8.1845 亿美元，复合年增长率为 7.14%。

主要市场统计数据
基准年2024年	4.7123亿美元
预计2025年	5.0313亿美元
预测年份：2032年	8.1845亿美元
复合年增长率（%）	7.14%

影响球孢子菌病临床挑战、诊断和治疗以及策略重点的系统性因素的全面情况概述

球孢子菌病在流行地区通常被称为山谷热，它在临床管理、公共卫生监测和药物供应方面面临多方面的挑战。本导论分析综合了当代临床实践、诊断演变和治疗方法，旨在解释为什么临床、监管和商业领域的相关人员必须重新调整其优先事项。由于该疾病表现形式多样，从自限性呼吸道疾病到慢性播散性全身性疾病，及时诊断和适当的抗真菌治疗至关重要，同时还需要开发更有效的诊断和治疗方法方法。

抗真菌药物研发的最新趋势、分子和血清学诊断技术的进步，以及对免疫力缺乏患者和特定人群等弱势群体的日益关注，正在共同重塑治疗模式。同时，医疗服务提供模式的转变和支付方动态的演变，正在影响住院和门诊病患的医疗服务取得方式。本介绍将为深入评估系统性转变、政策影响、细分领域特定影响、区域差异和实务建议奠定基础。其目的是为领导者提供简洁而坚实的基础，帮助他们解读下游分析，并在加速的临床和商业性变革中果断采取行动。

不断发展的临床诊断和治疗方法与供应链弹性和不断变化的流行病学相交织，重塑护理途径和相关人员策略

由于诊断方法的进步、治疗策略的改进以及整个公共卫生系统意识的提高，球孢子菌病的现状正在发生重大变化。照护现场和实验室分子检测缩短了诊断时间，使临床医生能够更早启动针对性的抗真菌治疗，从而改变了医院的利用率和门诊追踪模式。同时，人口流动和气候变迁使得人们在历史流行区以外对该疾病的认识有所提高，迫使相关人员重新评估监测框架和临床医生教育计画。

治疗方案组合也在不断发展。虽然基于对药物动力学、药物交互作用和患者耐受性的更深入理解，优化Azole药物的选择已成为新兴趋势，但静脉注射製剂对于需要住院治疗的重症或播散性病例仍然至关重要。这些临床改进正在推动治疗流程的修订，并影响医院、诊所和专科中心之间的需求分配。同时，随着製造商和经销商适应原物料采购、监管复杂性和通路动态的变化，供应链韧性正成为一项策略重点。总而言之，这些变化需要对临床开发、商业营运和公共卫生政策进行全面规划，以将创新转化为改善的患者疗效和持续的可近性。

不断变化的贸易政策和关税迫使供应链重组和筹资策略改革，以维持抗真菌治疗和临床用品的供应

关税政策变化的累积影响正在波及医药供应链和成本结构，显着影响抗真菌治疗药物及相关临床材料。进口活性药物原料药和成品关税的提高，推动了供应链多元化的需求，促使製造商和采购团队考虑其他筹资策略和不易受关税波动影响的区域製造地。此类重组不仅影响定价，还影响库存策略以及与经销商和医疗保健提供者的合约安排。

关税主导的成本压力可能会加速大型医院系统和专科中心之间的采购整合，这些机构拥有更强的谈判能力和更完善的供应链。同时，小型诊所和独立医疗保健机构可能面临利润空间缩减，并且更加依赖批发商和第三方物流供应商来管理采购的复杂性。应对这些动态的製造商可能会优先考虑能够平衡临床效用和供应链可行性的剂型和给药途径，例如优先考虑更稳定、更易于分销的慢性病口服剂型。总体而言，这种关税环境凸显了主动的供应链规划、情境规划和策略伙伴关係关係的重要性，以确保获得基本抗真菌药物，同时维持医疗机构的可负担性。

细緻的临床和商业观点揭示了药物类别、感染表型、给药途径、分销管道、最终用户和患者类型的需求

细緻的细分视角阐明了治疗方法选择和护理途径在临床和商业性上的交叉方式。依药物类别分析将市场分为Azole和Polyenes，Azole又细分为Fluconazole、Itraconazole、Ketoconazole和Voriconazole，每种药物均具有独特的疗效-耐受性和药物交互作用特征，可为急性、慢性和播散性疾病的治疗方案选择提供参考。感染类型（慢性与播散性）决定了何时口服门诊治疗有利，以及何时静脉注射对于初始住院治疗至关重要。粗球孢子菌和波萨达斯球孢子菌在种级水平上的差异，有助于区分诊断和流行病学差异，这可能会影响社区监测和临床试验设计。

给药途径仍然是一个关键的细分轴心，静脉注射仅用于需要快速达到治疗水平的严重疾病，而口服製剂则有利于门诊的长期管理并提高患者的依从性。将分销管道细分为线下和线上零售，揭示了不断变化的患者获取模式，数位药房和电子处方笺正在改变履约时间表和依从性支援。将最终使用者（诊所、医院、研究机构和专科中心）细分，突显了多样化的采购行为和临床工作流程，进而影响产品的商业性定位和支援方式。最后，将患者类型细分为成人和小儿科，突显了不同剂型的安全性特征以及支持儿童使用的临床证据的需求。结合这些细分维度，可以创建一个矩阵，为整个护理过程中的产品开发优先顺序、商业性获取策略和临床教育工作提供资讯。

地方性临床能力和法律规范的地区差异导致全部区域医疗准入途径和策略重点不同

区域动态对不同地区疾病发生率相关的临床实务和市场行为有显着影响。在美洲，疫情热点地区集中了临床专业知识、诊断基础设施和专业的医疗途径，有助于快速识别病例并启动治疗。同时，这些地区内部和跨地区的人口流动正在传播临床意识，并推动对可扩展诊断的需求。中东和非洲地区呈现出一种异质性格局，零星的输入性病例与特定医疗机构不断增强的诊断能力并存，这促使开展有针对性的临床医生教育和跨境监测合作，以确保及时识别和管理。

儘管亚太地区对抗真菌药物的认知度正在提高，抗真菌药物的可及性仍然不均衡，医院基础设施和分销网络的差异影响了都市区地区的治疗实践。区域法律规范和报销环境进一步影响了新诊断和治疗方法的采用，因此需要製定兼顾当地政策、临床规范和经销伙伴关係的打入市场策略。在各个地区，协调一致的实验室能力建设和第一线临床医生的继续医学教育对于改善治疗结果、减少诊断和治疗启动的延误仍然至关重要。

竞争策略强调证据生成、优化、经销伙伴和诊断整合，以向临床医生和医疗保健提供者提案差异化的价值主张

纵观竞争格局，各公司和机构正在采用差异化策略来满足临床需求，并巩固其在抗真菌治疗和诊断领域的地位。一些公司专注于透过研究者主导的临床实验和真实世界数据收集来增强临床证据，以证明药物在慢性和播散性疾病中的相对疗效和长期安全性。其他机构则优先考虑配方创新、优化生物有效性，并制定患者友善的给药方案，以支持门诊患者的依从性。随着利益相关人员寻求在监管和关税压力下简化分销流程并确保供应的连续性，製造商、合约研究组织和专业药房之间的策略联盟日益普遍。

同时，诊断公司正在投资更灵敏的检测方法和多路復用平台，以快速区分病原体，从而支持标靶治疗选择。医院、诊所和研究机构等机构终端使用者正在加大对临床医生培训和抗菌药物管理计画的投资，以确保抗真菌药物的选择符合最佳实践指南。总而言之，这些企业级措施反映出企业正转向整合产品服务，将治疗与诊断和教育支援相结合，为医生付款人和采购团队提供差异化的价值提案。

领导者应采取切实可行的策略行动，协调开发、分销和临床教育工作，同时加强供应链和市场进入途径

产业领导者应采取一系列切实可行的措施，充分利用临床进展并降低营运风险。首先，应将临床开发重点与未满足的需求结合，投资进行比较研究，明确Fluconazole、Itraconazole、Ketoconazole和Voriconazole在不同患者亚群中的相对优势，并支持儿科製剂改进研究。其次，应加强供应链韧性，实现原料药来源多元化，并探索区域製造伙伴关係，以降低贸易中断和关税相关成本衝击带来的风险。

第三，制定全面的打入市场策略，整合线下和线上零售管道，并认识到电子处方和数位药房服务将如何重塑患者的履约和依从性。第四，积极与终端使用者诊所、医院、研究机构和专科中心合作，提供临床教育和管理资源，以促进在慢性和播散性病例中合理使用抗真菌药物。最后，寻求与诊断开发人员的合作机会，共同开发捆绑式解决方案，简化从诊断到治疗的流程，并透过展示临床和营运价值来支持与付款方的讨论。这些建议优先考虑灵活性和整合性，以确保持续的可近性和改善的患者治疗效果，同时应对政策和市场的复杂性。

严格的多源研究框架，整合文献综合、专家访谈和资料三角测量，检验临床操作和政策见解

本分析所依据的研究将多源情报与方法检验相结合，以确保研究结果可靠且可操作。二次研究涵盖同行评审文献、临床指南、监管出版物和公共卫生监测报告，旨在建立涵盖疾病流行病学、诊断性能和治疗方法的全面依证。此外，我们也进行了有针对性的一手研究，包括对临床专家、医院药剂师、供应链经理和经销商进行结构化访谈，以增强研究的有效性，并检验新兴主题。

数据合成运用三角测量技术，将临床证据、采购惯例和当地政策背景的研究结果进行整合。调查方法和数据来源优先考虑引文透明度和对证据品质的严格评估，将观察性数据与真实世界数据相联繫，同时强调高品质的随机试验和检验的诊断性能测试。对于存在差距的地方，专家咨询提供了解释指导，以确保结论在临床上有效且在操作上适当。由此产生的分析框架可支援产生可重复的见解，并可适用于持续监测和定期报告更新。

临床实务与政策要求的结合凸显了采取实证协作策略以改善获取结果和供应弹性的必要性

总而言之，围绕球孢子菌病的临床、商业性和政策格局正在不断演变，需要采取协调一致的应对措施，将诊断和治疗供应链管理与临床医生的参与结合起来。分子和血清学检测的进步，加上Azole和Polyenes在慢性和播散性疾病中更先进的治疗应用，如果透过教育和管理转化为实践，将为改善患者预后创造机会。同时，贸易政策和关税的发展凸显了积极主动的供应链规划以及策略性地分配製造和采购资源以维持医疗服务的连续性的重要性。

製造商、医疗保健提供者和付款人之间的策略合作对于将科学和营运方面的进步转化为可近性和疗效的实际改善至关重要。持续投资于证据生成，加上本地定制的可及性策略和综合诊断与治疗解决方案，将使相关人员能够应对不确定性，并为受影响的患者提供更好的护理。本综述为明智的决策奠定了基础，并强调了在不断变化的流行病学和政策动态环境中采取灵活、循证驱动方法的必要性。

目录

第一章：前言

第二章调查方法

第三章执行摘要

第四章 市场概况

第五章 市场洞察

• 气候变迁和人口流动导致球孢子菌病发生率增加
• 新型抗真菌药物在山谷热后期临床试验的进展
• 整合快速POC诊断平台，提升早期检测能力
• 随着私人和公共资金的增加，疫苗开发平臺不断推进
• 影响疾病管理报销和覆盖范围的地方政府医疗保健政策的修订
• 扩大远端医疗服务，支持对球孢子菌病患者的远端监控
• 流行地区对包含球孢子菌病目标的多重呼吸道检测板的需求不断增加
• 利用人工智慧驱动的影像分析来区分肺结节和恶性肿瘤
• 人们越来越有兴趣教育基层医疗提供者有关山谷热的鑑别诊断，以减少因误诊而造成的延误。

第六章：2025年美国关税的累积影响

第七章：人工智慧的累积影响，2025年

8. 球孢子菌病市场（依药物类别）

• Azole
  • Fluconazole
  • Itraconazole
  • Ketoconazole
  • Voriconazole
• Polyenes

9. 球孢子菌病市场（依感染类型）

• 慢性的
• 传播

10. 球孢子菌病市场（依种类）

• 粗球孢子菌
• 波萨达斯球孢子菌

11. 球孢子菌病市场（依给药途径）

• 静脉
• 口服

12. 球孢子菌病市场（依分销管道）

• 线下零售
• 网路零售

13. 球孢子菌病市场（依最终用户）

• 诊所
• 医院
• 研究所
• 专业中心

14. 球孢子菌病市场（依患者类型）

• 成人
• 孩子们

15. 球孢子菌病市场（按地区）

• 美洲
  • 北美洲
  • 拉丁美洲
• 欧洲、中东和非洲
  • 欧洲
  • 中东
  • 非洲
• 亚太地区

16. 球孢子菌病市场（依类别）

• ASEAN
• GCC
• EU
• BRICS
• G7
• NATO

17. 球孢子菌病市场（依国家）

• 美国
• 加拿大
• 墨西哥
• 巴西
• 英国
• 德国
• 法国
• 俄罗斯
• 义大利
• 西班牙
• 中国
• 印度
• 日本
• 澳洲
• 韩国

第十八章竞争格局

• 2024年市占率分析
• 2024年FPNV定位矩阵
• 竞争分析
  • Quest Diagnostics Incorporated
  • Meridian Bioscience, Inc.
  • Laboratory Corporation of America Holdings
  • IMMY
  • Mayne Pharma Group Limited
  • Meridian Bioscience, Inc.
  • Mycovia Pharmaceuticals, Inc.
  • Scynexis, Inc.
  • Pfizer Inc.
  • Gilead Sciences, Inc.
  • Merck & Co., Inc.
  • CELLTRION INC.
  • Shionogi & Co., Ltd.

The Coccidioidomycosis Market is projected to grow by USD 818.45 million at a CAGR of 7.14% by 2032.

KEY MARKET STATISTICS
Base Year [2024]	USD 471.23 million
Estimated Year [2025]	USD 503.13 million
Forecast Year [2032]	USD 818.45 million
CAGR (%)	7.14%

Comprehensive contextual overview of coccidioidomycosis clinical challenges and systemic factors reshaping diagnosis treatment delivery and strategic priorities

Coccidioidomycosis, often referred to as valley fever in endemic regions, presents a multifaceted challenge spanning clinical management, public health surveillance, and pharmaceutical supply. This introductory analysis synthesizes contemporary clinical practice, diagnostic evolution, and therapeutic approaches to frame why stakeholders across clinical, regulatory, and commercial spheres must recalibrate priorities. The disease's variable presentation, ranging from self-limited respiratory illness to chronic and disseminated systemic disease, places a premium on timely diagnosis and appropriate antifungal therapy, while also driving demand for more effective diagnostics and treatment pathways.

Recent advances in antifungal development, improvements in molecular and serologic diagnostics, and heightened focus on vulnerable populations such as immunocompromised patients and certain demographic cohorts have collectively reshaped care paradigms. Simultaneously, shifting healthcare delivery models and evolving payer dynamics influence how treatments are accessed across inpatient and outpatient settings. This introduction sets the stage for a deeper assessment of systemic shifts, policy impacts, segmentation-specific implications, regional nuances, and practical recommendations that follow. The goal is to equip leaders with a concise yet robust foundation to interpret downstream analyses and to act decisively in an environment of accelerating clinical and commercial change.

Evolving clinical diagnostics and therapeutic modalities intersect with supply chain resilience and shifting epidemiology to reshape care pathways and stakeholder strategies

The landscape for coccidioidomycosis is undergoing transformative shifts driven by advances in diagnostics, therapeutic strategy refinement, and expanded awareness across public health systems. Point-of-care and laboratory-based molecular assays are shortening time to diagnosis, enabling clinicians to initiate targeted antifungal therapy earlier, which in turn changes patterns of hospital utilization and outpatient follow-up. Concurrently, growing recognition of the disease outside historically endemic zones, influenced by population mobility and climate-related shifts, has compelled stakeholders to reassess surveillance frameworks and clinician education programs.

Therapeutic portfolios are also evolving. There is a clear trend toward optimizing azole therapy selection based on better understanding of pharmacokinetics, drug-drug interactions, and patient tolerance, while intravenous formulations remain essential for severe and disseminated cases that require hospital-based care. These clinical refinements are prompting revisions in treatment algorithms and influencing the distribution of demand across hospitals, clinics, and specialty centers. In parallel, supply chain resilience is becoming a strategic priority as manufacturers and distributors adapt to changes in raw material sourcing, regulatory complexity, and channel dynamics. Taken together, these shifts necessitate integrated planning across clinical development, commercial operations, and public health policy to translate innovation into improved patient outcomes and sustained access.

Shifts in trade policy and tariff measures are compelling supply chain realignment and procurement strategy reform to preserve access to antifungal treatments and clinical supplies

The cumulative impact of tariff policy developments has rippled through pharmaceutical supply chains and cost structures with material implications for antifungal therapies and related clinical supplies. Increased duties on imported active pharmaceutical ingredients and finished formulations have heightened the need for supply chain diversification, prompting manufacturers and procurement teams to evaluate alternative sourcing strategies and to consider regional manufacturing hubs that reduce exposure to tariff volatility. This realignment affects not only pricing considerations but also inventory strategies and contractual arrangements with distributors and healthcare providers.

Tariff-driven cost pressures can accelerate the consolidation of purchasing among larger hospital systems and specialty centers that possess greater negotiating power and supply chain sophistication. At the same time, smaller clinics and independent providers may face tighter margins and increased reliance on wholesalers and third-party logistics providers to manage procurement complexity. Manufacturers responding to these dynamics may prioritize product formulations and routes of administration that balance clinical utility with supply chain feasibility, such as favoring oral agents for chronic management where stability and distribution are more straightforward. Overall, the tariff environment underscores the importance of proactive supply chain mapping, scenario planning, and strategic partnerships to safeguard access to essential antifungal therapies while maintaining affordability across care settings.

Segmented clinical and commercial perspectives reveal differentiated needs across drug classes infection phenotypes routes of administration distribution channels end users and patient types

A nuanced segmentation lens reveals how therapeutic choices and care pathways intersect with distinct clinical and commercial imperatives. When analyzed by drug class, the market divides between azoles and polyenes, with azoles further differentiated into fluconazole, itraconazole, ketoconazole, and voriconazole, each offering a distinct efficacy tolerability and drug interaction profile that informs regimen selection for acute chronic and disseminated presentations. Differentiation by infection type-chronic versus disseminated-clarifies where outpatient oral therapies predominate versus where intravenous interventions are essential for initial management in hospital settings. Species-level considerations between Coccidioides immitis and Coccidioides posadasii contribute to subtle diagnostic and epidemiologic distinctions that can influence regional surveillance and clinical trial design.

Route of administration remains a pivotal segmentation axis, with intravenous delivery reserved for severe disease requiring rapid therapeutic levels and oral formulations facilitating long-term management and improved patient adherence in ambulatory care. Distribution channel segmentation into offline retail and online retail highlights evolving patient access patterns, with digital pharmacies and e-prescribing altering fulfillment timelines and adherence support. End user segmentation across clinics hospitals research institutes and specialty centers underscores diverse procurement behaviors and clinical workflows, affecting how products are positioned and supported commercially. Finally, patient type segmentation into adults and pediatrics emphasizes distinct dosing formulations safety profiles and the need for tailored clinical evidence to support pediatric use. Together these segmentation dimensions create a matrix that informs product development priorities, commercial access strategies, and clinical education efforts across the care continuum.

Regional variations in endemicity clinical capabilities and regulatory frameworks drive distinct access pathways and strategic priorities across the Americas EMEA and Asia Pacific

Regional dynamics exert a profound influence on disease incidence clinical practice and market behavior across distinct geographies. In the Americas, endemic hotspots concentrate clinical expertise, diagnostic infrastructure, and specialty care pathways that shape rapid case identification and treatment initiation, while population mobility within and beyond these regions spreads clinical awareness and drives demand for scalable diagnostics. Europe Middle East & Africa present heterogenous landscapes where sporadic imported cases coexist with growing diagnostic capacity in select centers, prompting targeted clinician education and cross-border surveillance collaborations to ensure timely recognition and management.

Asia-Pacific shows a mix of emerging awareness and variable access to antifungal therapies, with disparities in hospital infrastructure and distribution networks influencing how care is delivered in urban centers versus peripheral regions. Regional regulatory frameworks and reimbursement environments further modulate adoption of newer diagnostics and therapeutics, necessitating tailored market entry strategies that account for local policy, clinical practice norms, and distribution partnerships. Across all regions, coordinated capacity-building for laboratories and continuing medical education for frontline clinicians remains critical to improving outcomes and reducing delays in diagnosis and treatment initiation.

Competitive strategies emphasize evidence generation formulation optimization distribution partnerships and diagnostics integration to create differentiated value propositions for clinicians and providers

Across the competitive landscape, companies and institutions are adopting differentiated strategies to address clinical needs and to strengthen their position in antifungal therapeutics and diagnostics. Some organizations concentrate on enhancing clinical evidence through investigator-initiated studies and real-world data collection to demonstrate comparative effectiveness and long-term safety in chronic and disseminated disease. Others prioritize formulation innovation, optimizing oral bioavailability or creating patient-friendly dosing regimens that support adherence in outpatient settings. Strategic partnerships between manufacturers, contract development organizations, and specialty pharmacies are increasingly common as stakeholders seek to streamline distribution and to ensure continuity of supply in the face of regulatory and tariff pressures.

In parallel, diagnostic firms are investing in higher-sensitivity assays and multiplex platforms that enable faster differentiation of etiologic agents, thereby supporting targeted therapy selection. Institutional end users such as hospitals, clinics, and research institutes are escalating investments in clinician training and in antimicrobial stewardship programs that align antifungal selection with best practice guidelines. Collectively, these company-level moves reflect a shift toward integrated offerings that combine therapeutic agents with diagnostic and educational support to create differentiated value propositions for physicians payers and procurement teams.

Practical strategic actions for leaders to align development distribution and clinical education efforts while strengthening supply chains and market access pathways

Industry leaders should adopt a pragmatic set of actions to capitalize on clinical advances and to mitigate operational risks. First, align clinical development priorities with unmet needs by investing in comparative studies that clarify the relative advantages of fluconazole itraconazole ketoconazole and voriconazole across patient subgroups, while also supporting research into improved formulations for pediatric use. Second, strengthen supply chain resilience by diversifying sourcing for active pharmaceutical ingredients and by exploring regional manufacturing partnerships that reduce exposure to trade disruptions and tariff-related cost shocks.

Third, develop comprehensive market access strategies that incorporate both offline retail and online retail channels, recognizing how e-prescribing and digital pharmacy services reshape patient fulfillment and adherence. Fourth, engage proactively with end users-clinics hospitals research institutes and specialty centers-to deliver tailored clinical education and stewardship resources that facilitate appropriate antifungal use across chronic and disseminated cases. Finally, pursue collaborative opportunities with diagnostic developers to co-develop bundled solutions that streamline diagnosis-to-treatment pathways and support payer discussions by demonstrating clinical and operational value. These recommendations prioritize agility and integration to ensure sustained access and improved patient outcomes while navigating policy and market complexity.

Rigorous multi-source research framework integrating literature synthesis expert interviews and data triangulation to validate clinical operational and policy insights

The research underpinning this analysis combined multi-source intelligence and methodical validation to ensure robust, actionable findings. Secondary research encompassed peer-reviewed literature clinical guidelines regulatory publications and public health surveillance reports to construct a comprehensive evidence base on disease epidemiology diagnostic performance and therapeutic approaches. This literature-driven foundation was augmented by targeted primary research consisting of structured interviews with clinical experts, hospital pharmacists, supply chain managers, and distributors to capture real-world operational insights and to validate emergent themes.

Data synthesis employed triangulation techniques to reconcile findings across clinical evidence, procurement practices, and regional policy contexts. The methodology prioritized transparency in source attribution and critical assessment of evidence quality, placing greater weight on high-quality randomized trials and validated diagnostic performance studies while contextualizing observational and real-world data. Where gaps existed, expert elicitation provided interpretive guidance to ensure conclusions remained clinically plausible and operationally relevant. The resulting analytical framework supports reproducible insight generation and can be adapted for ongoing surveillance and periodic report updates.

Synthesis of clinical operational and policy imperatives highlighting the need for coordinated evidence aligned strategies to improve access outcomes and supply resilience

In conclusion, the evolving clinical, commercial, and policy landscape around coccidioidomycosis requires coordinated responses that bridge diagnostics therapeutics supply chain management and clinician engagement. Advances in molecular and serologic testing, coupled with more refined therapeutic use of azoles and polyenes across chronic and disseminated presentations, create opportunities to improve patient outcomes when translated into practice through education and stewardship. At the same time, trade policy and tariff developments emphasize the importance of proactive supply chain planning and the strategic allocation of manufacturing and procurement resources to maintain continuity of care.

Strategic alignment among manufacturers distributors providers and payers will be essential to converting scientific and operational progress into tangible improvements in access and outcomes. Continued investment in evidence generation, coupled with regionally tailored access strategies and integrated diagnostic-treatment solutions, will enable stakeholders to navigate uncertainty and to deliver better care for affected patients. This synthesis offers a basis for informed decision-making and underscores the necessity of agile, evidence-aligned approaches in an environment of shifting epidemiology and policy dynamics.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Growing incidence of coccidioidomycosis driven by climate change and population migration
• 5.2. Advancement of novel antifungal agents in late stage clinical trials for valley fever
• 5.3. Integration of rapid point of care diagnostic platforms to improve early detection
• 5.4. Progress in vaccine development pipelines amid increasing private and public funding
• 5.5. Municipal healthcare policy revisions affecting disease management reimbursement and coverage
• 5.6. Expansion of telemedicine services to support remote monitoring of coccidioidomycosis patients
• 5.7. Increasing demand for multiplex respiratory panels incorporating coccidioidomycosis targets in endemic settings
• 5.8. Adoption of artificial intelligence driven imaging analysis to differentiate coccidioidomycosis lung nodules from malignancy
• 5.9. Rising interest in educating primary care providers on differential diagnosis of valley fever to reduce misdiagnosis delays

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Coccidioidomycosis Market, by Drug Class

• 8.1. Azoles
  • 8.1.1. Fluconazole
  • 8.1.2. Itraconazole
  • 8.1.3. Ketoconazole
  • 8.1.4. Voriconazole
• 8.2. Polyenes

9. Coccidioidomycosis Market, by Infection Type

• 9.1. Chronic
• 9.2. Disseminated

10. Coccidioidomycosis Market, by Species

• 10.1. Coccidioides Immitis
• 10.2. Coccidioides Posadasii

11. Coccidioidomycosis Market, by Route Of Administration

• 11.1. Intravenous
• 11.2. Oral

12. Coccidioidomycosis Market, by Distribution Channel

• 12.1. Offline Retail
• 12.2. Online Retail

13. Coccidioidomycosis Market, by End User

• 13.1. Clinics
• 13.2. Hospitals
• 13.3. Research Institutes
• 13.4. Specialty Centers

14. Coccidioidomycosis Market, by Patient Type

• 14.1. Adults
• 14.2. Pediatrics

15. Coccidioidomycosis Market, by Region

• 15.1. Americas
  • 15.1.1. North America
  • 15.1.2. Latin America
• 15.2. Europe, Middle East & Africa
  • 15.2.1. Europe
  • 15.2.2. Middle East
  • 15.2.3. Africa
• 15.3. Asia-Pacific

16. Coccidioidomycosis Market, by Group

• 16.1. ASEAN
• 16.2. GCC
• 16.3. European Union
• 16.4. BRICS
• 16.5. G7
• 16.6. NATO

17. Coccidioidomycosis Market, by Country

• 17.1. United States
• 17.2. Canada
• 17.3. Mexico
• 17.4. Brazil
• 17.5. United Kingdom
• 17.6. Germany
• 17.7. France
• 17.8. Russia
• 17.9. Italy
• 17.10. Spain
• 17.11. China
• 17.12. India
• 17.13. Japan
• 17.14. Australia
• 17.15. South Korea

18. Competitive Landscape

• 18.1. Market Share Analysis, 2024
• 18.2. FPNV Positioning Matrix, 2024
• 18.3. Competitive Analysis
  • 18.3.1. Quest Diagnostics Incorporated
  • 18.3.2. Meridian Bioscience, Inc.
  • 18.3.3. Laboratory Corporation of America Holdings
  • 18.3.4. IMMY
  • 18.3.5. Mayne Pharma Group Limited
  • 18.3.6. Meridian Bioscience, Inc.
  • 18.3.7. Mycovia Pharmaceuticals, Inc.
  • 18.3.8. Scynexis, Inc.
  • 18.3.9. Pfizer Inc.
  • 18.3.10. Gilead Sciences, Inc.
  • 18.3.11. Merck & Co., Inc.
  • 18.3.12. CELLTRION INC.
  • 18.3.13. Shionogi & Co., Ltd.

LIST OF FIGURES

• FIGURE 1. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, 2018-2032 (USD MILLION)
• FIGURE 2. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY DRUG CLASS, 2024 VS 2032 (%)
• FIGURE 3. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY DRUG CLASS, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 4. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY INFECTION TYPE, 2024 VS 2032 (%)
• FIGURE 5. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY INFECTION TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 6. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY SPECIES, 2024 VS 2032 (%)
• FIGURE 7. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY SPECIES, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 8. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2032 (%)
• FIGURE 9. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 10. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2032 (%)
• FIGURE 11. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 12. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY END USER, 2024 VS 2032 (%)
• FIGURE 13. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 14. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY PATIENT TYPE, 2024 VS 2032 (%)
• FIGURE 15. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY PATIENT TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 16. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 17. AMERICAS COCCIDIOIDOMYCOSIS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 18. NORTH AMERICA COCCIDIOIDOMYCOSIS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 19. LATIN AMERICA COCCIDIOIDOMYCOSIS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 20. EUROPE, MIDDLE EAST & AFRICA COCCIDIOIDOMYCOSIS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 21. EUROPE COCCIDIOIDOMYCOSIS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 22. MIDDLE EAST COCCIDIOIDOMYCOSIS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 23. AFRICA COCCIDIOIDOMYCOSIS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 24. ASIA-PACIFIC COCCIDIOIDOMYCOSIS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 25. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 26. ASEAN COCCIDIOIDOMYCOSIS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 27. GCC COCCIDIOIDOMYCOSIS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 28. EUROPEAN UNION COCCIDIOIDOMYCOSIS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 29. BRICS COCCIDIOIDOMYCOSIS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 30. G7 COCCIDIOIDOMYCOSIS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 31. NATO COCCIDIOIDOMYCOSIS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 32. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 33. COCCIDIOIDOMYCOSIS MARKET SHARE, BY KEY PLAYER, 2024
• FIGURE 34. COCCIDIOIDOMYCOSIS MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

• TABLE 1. COCCIDIOIDOMYCOSIS MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
• TABLE 3. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, 2018-2024 (USD MILLION)
• TABLE 4. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, 2025-2032 (USD MILLION)
• TABLE 5. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
• TABLE 6. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
• TABLE 7. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY AZOLES, 2018-2024 (USD MILLION)
• TABLE 8. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY AZOLES, 2025-2032 (USD MILLION)
• TABLE 9. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY AZOLES, BY REGION, 2018-2024 (USD MILLION)
• TABLE 10. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY AZOLES, BY REGION, 2025-2032 (USD MILLION)
• TABLE 11. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY AZOLES, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 12. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY AZOLES, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 13. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY AZOLES, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 14. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY AZOLES, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 15. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY FLUCONAZOLE, BY REGION, 2018-2024 (USD MILLION)
• TABLE 16. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY FLUCONAZOLE, BY REGION, 2025-2032 (USD MILLION)
• TABLE 17. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY FLUCONAZOLE, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 18. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY FLUCONAZOLE, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 19. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY FLUCONAZOLE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 20. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY FLUCONAZOLE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 21. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY ITRACONAZOLE, BY REGION, 2018-2024 (USD MILLION)
• TABLE 22. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY ITRACONAZOLE, BY REGION, 2025-2032 (USD MILLION)
• TABLE 23. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY ITRACONAZOLE, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 24. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY ITRACONAZOLE, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 25. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY ITRACONAZOLE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 26. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY ITRACONAZOLE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 27. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY KETOCONAZOLE, BY REGION, 2018-2024 (USD MILLION)
• TABLE 28. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY KETOCONAZOLE, BY REGION, 2025-2032 (USD MILLION)
• TABLE 29. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY KETOCONAZOLE, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 30. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY KETOCONAZOLE, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 31. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY KETOCONAZOLE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 32. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY KETOCONAZOLE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 33. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY VORICONAZOLE, BY REGION, 2018-2024 (USD MILLION)
• TABLE 34. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY VORICONAZOLE, BY REGION, 2025-2032 (USD MILLION)
• TABLE 35. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY VORICONAZOLE, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 36. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY VORICONAZOLE, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 37. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY VORICONAZOLE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 38. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY VORICONAZOLE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 39. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY POLYENES, BY REGION, 2018-2024 (USD MILLION)
• TABLE 40. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY POLYENES, BY REGION, 2025-2032 (USD MILLION)
• TABLE 41. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY POLYENES, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 42. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY POLYENES, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 43. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY POLYENES, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 44. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY POLYENES, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 45. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY INFECTION TYPE, 2018-2024 (USD MILLION)
• TABLE 46. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY INFECTION TYPE, 2025-2032 (USD MILLION)
• TABLE 47. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY CHRONIC, BY REGION, 2018-2024 (USD MILLION)
• TABLE 48. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY CHRONIC, BY REGION, 2025-2032 (USD MILLION)
• TABLE 49. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY CHRONIC, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 50. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY CHRONIC, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 51. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY CHRONIC, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 52. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY CHRONIC, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 53. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY DISSEMINATED, BY REGION, 2018-2024 (USD MILLION)
• TABLE 54. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY DISSEMINATED, BY REGION, 2025-2032 (USD MILLION)
• TABLE 55. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY DISSEMINATED, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 56. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY DISSEMINATED, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 57. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY DISSEMINATED, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 58. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY DISSEMINATED, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 59. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY SPECIES, 2018-2024 (USD MILLION)
• TABLE 60. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY SPECIES, 2025-2032 (USD MILLION)
• TABLE 61. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY COCCIDIOIDES IMMITIS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 62. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY COCCIDIOIDES IMMITIS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 63. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY COCCIDIOIDES IMMITIS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 64. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY COCCIDIOIDES IMMITIS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 65. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY COCCIDIOIDES IMMITIS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 66. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY COCCIDIOIDES IMMITIS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 67. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY COCCIDIOIDES POSADASII, BY REGION, 2018-2024 (USD MILLION)
• TABLE 68. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY COCCIDIOIDES POSADASII, BY REGION, 2025-2032 (USD MILLION)
• TABLE 69. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY COCCIDIOIDES POSADASII, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 70. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY COCCIDIOIDES POSADASII, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 71. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY COCCIDIOIDES POSADASII, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 72. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY COCCIDIOIDES POSADASII, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 73. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
• TABLE 74. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
• TABLE 75. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 76. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 77. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 78. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 79. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 80. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 81. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY ORAL, BY REGION, 2018-2024 (USD MILLION)
• TABLE 82. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY ORAL, BY REGION, 2025-2032 (USD MILLION)
• TABLE 83. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY ORAL, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 84. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY ORAL, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 85. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 86. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY ORAL, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 87. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 88. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
• TABLE 89. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY OFFLINE RETAIL, BY REGION, 2018-2024 (USD MILLION)
• TABLE 90. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY OFFLINE RETAIL, BY REGION, 2025-2032 (USD MILLION)
• TABLE 91. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY OFFLINE RETAIL, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 92. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY OFFLINE RETAIL, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 93. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY OFFLINE RETAIL, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 94. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY OFFLINE RETAIL, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 95. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY ONLINE RETAIL, BY REGION, 2018-2024 (USD MILLION)
• TABLE 96. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY ONLINE RETAIL, BY REGION, 2025-2032 (USD MILLION)
• TABLE 97. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY ONLINE RETAIL, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 98. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY ONLINE RETAIL, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 99. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY ONLINE RETAIL, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 100. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY ONLINE RETAIL, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 101. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 102. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 103. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY CLINICS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 104. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY CLINICS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 105. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY CLINICS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 106. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY CLINICS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 107. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 108. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 109. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 110. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 111. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 112. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 113. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 114. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 115. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2024 (USD MILLION)
• TABLE 116. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2025-2032 (USD MILLION)
• TABLE 117. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 118. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 119. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 120. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 121. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY SPECIALTY CENTERS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 122. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY SPECIALTY CENTERS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 123. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY SPECIALTY CENTERS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 124. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY SPECIALTY CENTERS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 125. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY SPECIALTY CENTERS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 126. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY SPECIALTY CENTERS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 127. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
• TABLE 128. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY PATIENT TYPE, 2025-2032 (USD MILLION)
• TABLE 129. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY ADULTS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 130. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY ADULTS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 131. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY ADULTS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 132. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY ADULTS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 133. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY ADULTS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 134. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY ADULTS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 135. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY PEDIATRICS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 136. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY PEDIATRICS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 137. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY PEDIATRICS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 138. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY PEDIATRICS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 139. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY PEDIATRICS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 140. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY PEDIATRICS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 141. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
• TABLE 142. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
• TABLE 143. AMERICAS COCCIDIOIDOMYCOSIS MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
• TABLE 144. AMERICAS COCCIDIOIDOMYCOSIS MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
• TABLE 145. AMERICAS COCCIDIOIDOMYCOSIS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
• TABLE 146. AMERICAS COCCIDIOIDOMYCOSIS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
• TABLE 147. AMERICAS COCCIDIOIDOMYCOSIS MARKET SIZE, BY AZOLES, 2018-2024 (USD MILLION)
• TABLE 148. AMERICAS COCCIDIOIDOMYCOSIS MARKET SIZE, BY AZOLES, 2025-2032 (USD MILLION)
• TABLE 149. AMERICAS COCCIDIOIDOMYCOSIS MARKET SIZE, BY INFECTION TYPE, 2018-2024 (USD MILLION)
• TABLE 150. AMERICAS COCCIDIOIDOMYCOSIS MARKET SIZE, BY INFECTION TYPE, 2025-2032 (USD MILLION)
• TABLE 151. AMERICAS COCCIDIOIDOMYCOSIS MARKET SIZE, BY SPECIES, 2018-2024 (USD MILLION)
• TABLE 152. AMERICAS COCCIDIOIDOMYCOSIS MARKET SIZE, BY SPECIES, 2025-2032 (USD MILLION)
• TABLE 153. AMERICAS COCCIDIOIDOMYCOSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
• TABLE 154. AMERICAS COCCIDIOIDOMYCOSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
• TABLE 155. AMERICAS COCCIDIOIDOMYCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 156. AMERICAS COCCIDIOIDOMYCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
• TABLE 157. AMERICAS COCCIDIOIDOMYCOSIS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 158. AMERICAS COCCIDIOIDOMYCOSIS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 159. AMERICAS COCCIDIOIDOMYCOSIS MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
• TABLE 160. AMERICAS COCCIDIOIDOMYCOSIS MARKET SIZE, BY PATIENT TYPE, 2025-2032 (USD MILLION)
• TABLE 161. NORTH AMERICA COCCIDIOIDOMYCOSIS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 162. NORTH AMERICA COCCIDIOIDOMYCOSIS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 163. NORTH AMERICA COCCIDIOIDOMYCOSIS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
• TABLE 164. NORTH AMERICA COCCIDIOIDOMYCOSIS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
• TABLE 165. NORTH AMERICA COCCIDIOIDOMYCOSIS MARKET SIZE, BY AZOLES, 2018-2024 (USD MILLION)
• TABLE 166. NORTH AMERICA COCCIDIOIDOMYCOSIS MARKET SIZE, BY AZOLES, 2025-2032 (USD MILLION)
• TABLE 167. NORTH AMERICA COCCIDIOIDOMYCOSIS MARKET SIZE, BY INFECTION TYPE, 2018-2024 (USD MILLION)
• TABLE 168. NORTH AMERICA COCCIDIOIDOMYCOSIS MARKET SIZE, BY INFECTION TYPE, 2025-2032 (USD MILLION)
• TABLE 169. NORTH AMERICA COCCIDIOIDOMYCOSIS MARKET SIZE, BY SPECIES, 2018-2024 (USD MILLION)
• TABLE 170. NORTH AMERICA COCCIDIOIDOMYCOSIS MARKET SIZE, BY SPECIES, 2025-2032 (USD MILLION)
• TABLE 171. NORTH AMERICA COCCIDIOIDOMYCOSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
• TABLE 172. NORTH AMERICA COCCIDIOIDOMYCOSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
• TABLE 173. NORTH AMERICA COCCIDIOIDOMYCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 174. NORTH AMERICA COCCIDIOIDOMYCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
• TABLE 175. NORTH AMERICA COCCIDIOIDOMYCOSIS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 176. NORTH AMERICA COCCIDIOIDOMYCOSIS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 177. NORTH AMERICA COCCIDIOIDOMYCOSIS MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
• TABLE 178. NORTH AMERICA COCCIDIOIDOMYCOSIS MARKET SIZE, BY PATIENT TYPE, 2025-2032 (USD MILLION)
• TABLE 179. LATIN AMERICA COCCIDIOIDOMYCOSIS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 180. LATIN AMERICA COCCIDIOIDOMYCOSIS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 181. LATIN AMERICA COCCIDIOIDOMYCOSIS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
• TABLE 182. LATIN AMERICA COCCIDIOIDOMYCOSIS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
• TABLE 183. LATIN AMERICA COCCIDIOIDOMYCOSIS MARKET SIZE, BY AZOLES, 2018-2024 (USD MILLION)
• TABLE 184. LATIN AMERICA COCCIDIOIDOMYCOSIS MARKET SIZE, BY AZOLES, 2025-2032 (USD MILLION)
• TABLE 185. LATIN AMERICA COCCIDIOIDOMYCOSIS MARKET SIZE, BY INFECTION TYPE, 2018-2024 (USD MILLION)
• TABLE 186. LATIN AMERICA COCCIDIOIDOMYCOSIS MARKET SIZE, BY INFECTION TYPE, 2025-2032 (USD MILLION)
• TABLE 187. LATIN AMERICA COCCIDIOIDOMYCOSIS MARKET SIZE, BY SPECIES, 2018-2024 (USD MILLION)
• TABLE 188. LATIN AMERICA COCCIDIOIDOMYCOSIS MARKET SIZE, BY SPECIES, 2025-2032 (USD MILLION)
• TABLE 189. LATIN AMERICA COCCIDIOIDOMYCOSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
• TABLE 190. LATIN AMERICA COCCIDIOIDOMYCOSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
• TABLE 191. LATIN AMERICA COCCIDIOIDOMYCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 192. LATIN AMERICA COCCIDIOIDOMYCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
• TABLE 193. LATIN AMERICA COCCIDIOIDOMYCOSIS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 194. LATIN AMERICA COCCIDIOIDOMYCOSIS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 195. LATIN AMERICA COCCIDIOIDOMYCOSIS MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
• TABLE 196. LATIN AMERICA COCCIDIOIDOMYCOSIS MARKET SIZE, BY PATIENT TYPE, 2025-2032 (USD MILLION)
• TABLE 197. EUROPE, MIDDLE EAST & AFRICA COCCIDIOIDOMYCOSIS MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
• TABLE 198. EUROPE, MIDDLE EAST & AFRICA COCCIDIOIDOMYCOSIS MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
• TABLE 199. EUROPE, MIDDLE EAST & AFRICA COCCIDIOIDOMYCOSIS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
• TABLE 200. EUROPE, MIDDLE EAST & AFRICA COCCIDIOIDOMYCOSIS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
• TABLE 201. EUROPE, MIDDLE EAST & AFRICA COCCIDIOIDOMYCOSIS MARKET SIZE, BY AZOLES, 2018-2024 (USD MILLION)
• TABLE 202. EUROPE, MIDDLE EAST & AFRICA COCCIDIOIDOMYCOSIS MARKET SIZE, BY AZOLES, 2025-2032 (USD MILLION)
• TABLE 203. EUROPE, MIDDLE EAST & AFRICA COCCIDIOIDOMYCOSIS MARKET SIZE, BY INFECTION TYPE, 2018-2024 (USD MILLION)
• TABLE 204. EUROPE, MIDDLE EAST & AFRICA COCCIDIOIDOMYCOSIS MARKET SIZE, BY INFECTION TYPE, 2025-2032 (USD MILLION)
• TABLE 205. EUROPE, MIDDLE EAST & AFRICA COCCIDIOIDOMYCOSIS MARKET SIZE, BY SPECIES, 2018-2024 (USD MILLION)
• TABLE 206. EUROPE, MIDDLE EAST & AFRICA COCCIDIOIDOMYCOSIS MARKET SIZE, BY SPECIES, 2025-2032 (USD MILLION)
• TABLE 207. EUROPE, MIDDLE EAST & AFRICA COCCIDIOIDOMYCOSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
• TABLE 208. EUROPE, MIDDLE EAST & AFRICA COCCIDIOIDOMYCOSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
• TABLE 209. EUROPE, MIDDLE EAST & AFRICA COCCIDIOIDOMYCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 210. EUROPE, MIDDLE EAST & AFRICA COCCIDIOIDOMYCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
• TABLE 211. EUROPE, MIDDLE EAST & AFRICA COCCIDIOIDOMYCOSIS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 212. EUROPE, MIDDLE EAST & AFRICA COCCIDIOIDOMYCOSIS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 213. EUROPE, MIDDLE EAST & AFRICA COCCIDIOIDOMYCOSIS MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
• TABLE 214. EUROPE, MIDDLE EAST & AFRICA COCCIDIOIDOMYCOSIS MARKET SIZE, BY PATIENT TYPE, 2025-2032 (USD MILLION)
• TABLE 215. EUROPE COCCIDIOIDOMYCOSIS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 216. EUROPE COCCIDIOIDOMYCOSIS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 217. EUROPE COCCIDIOIDOMYCOSIS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
• TABLE 218. EUROPE COCCIDIOIDOMYCOSIS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
• TABLE 219. EUROPE COCCIDIOIDOMYCOSIS MARKET SIZE, BY AZOLES, 2018-2024 (USD MILLION)
• TABLE 220. EUROPE COCCIDIOIDOMYCOSIS MARKET SIZE, BY AZOLES, 2025-2032 (USD MILLION)
• TABLE 221. EUROPE COCCIDIOIDOMYCOSIS MARKET SIZE, BY INFECTION TYPE, 2018-2024 (USD MILLION)
• TABLE 222. EUROPE COCCIDIOIDOMYCOSIS MARKET SIZE, BY INFECTION TYPE, 2025-2032 (USD MILLION)
• TABLE 223. EUROPE COCCIDIOIDOMYCOSIS MARKET SIZE, BY SPECIES, 2018-2024 (USD MILLION)
• TABLE 224. EUROPE COCCIDIOIDOMYCOSIS MARKET SIZE, BY SPECIES, 2025-2032 (USD MILLION)
• TABLE 225. EUROPE COCCIDIOIDOMYCOSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
• TABLE 226. EUROPE COCCIDIOIDOMYCOSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
• TABLE 227. EUROPE COCCIDIOIDOMYCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 228. EUROPE COCCIDIOIDOMYCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
• TABLE 229. EUROPE COCCIDIOIDOMYCOSIS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 230. EUROPE COCCIDIOIDOMYCOSIS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 231. EUROPE COCCIDIOIDOMYCOSIS MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
• TABLE 232. EUROPE COCCIDIOIDOMYCOSIS MARKET SIZE, BY PATIENT TYPE, 2025-2032 (USD MILLION)
• TABLE 233. MIDDLE EAST COCCIDIOIDOMYCOSIS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 234. MIDDLE EAST COCCIDIOIDOMYCOSIS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 235. MIDDLE EAST COCCIDIOIDOMYCOSIS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
• TABLE 236. MIDDLE EAST COCCIDIOIDOMYCOSIS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
• TABLE 237. MIDDLE EAST COCCIDIOIDOMYCOSIS MARKET SIZE, BY AZOLES, 2018-2024 (USD MILLION)
• TABLE 238. MIDDLE EAST COCCIDIOIDOMYCOSIS MARKET SIZE, BY AZOLES, 2025-2032 (USD MILLION)
• TABLE 239. MIDDLE EAST COCCIDIOIDOMYCOSIS MARKET SIZE, BY INFECTION TYPE, 2018-2024 (USD MILLION)
• TABLE 240. MIDDLE EAST COCCIDIOIDOMYCOSIS MARKET SIZE, BY INFECTION TYPE, 2025-2032 (USD MILLION)
• TABLE 241. MIDDLE EAST COCCIDIOIDOMYCOSIS MARKET SIZE, BY SPECIES, 2018-2024 (USD MILLION)
• TABLE 242. MIDDLE EAST COCCIDIOIDOMYCOSIS MARKET SIZE, BY SPECIES, 2025-2032 (USD MILLION)
• TABLE 243. MIDDLE EAST COCCIDIOIDOMYCOSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
• TABLE 244. MIDDLE EAST COCCIDIOIDOMYCOSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
• TABLE 245. MIDDLE EAST COCCIDIOIDOMYCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 246. MIDDLE EAST COCCIDIOIDOMYCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
• TABLE 247. MIDDLE EAST COCCIDIOIDOMYCOSIS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 248. MIDDLE EAST COCCIDIOIDOMYCOSIS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 249. MIDDLE EAST COCCIDIOIDOMYCOSIS MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
• TABLE 250. MIDDLE EAST COCCIDIOIDOMYCOSIS MARKET SIZE, BY PATIENT TYPE, 2025-2032 (USD MILLION)
• TABLE 251. AFRICA COCCIDIOIDOMYCOSIS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 252. AFRICA COCCIDIOIDOMYCOSIS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 253. AFRICA COCCIDIOIDOMYCOSIS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
• TABLE 254. AFRICA COCCIDIOIDOMYCOSIS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
• TABLE 255. AFRICA COCCIDIOIDOMYCOSIS MARKET SIZE, BY AZOLES, 2018-2024 (USD MILLION)
• TABLE 256. AFRICA COCCIDIOIDOMYCOSIS MARKET SIZE, BY AZOLES, 2025-2032 (USD MILLION)
• TABLE 257. AFRICA COCCIDIOIDOMYCOSIS MARKET SIZE, BY INFECTION TYPE, 2018-2024 (USD MILLION)
• TABLE 258. AFRICA COCCIDIOIDOMYCOSIS MARKET SIZE, BY INFECTION TYPE, 2025-2032 (USD MILLION)
• TABLE 259. AFRICA COCCIDIOIDOMYCOSIS MARKET SIZE, BY SPECIES, 2018-2024 (USD MILLION)
• TABLE 260. AFRICA COCCIDIOIDOMYCOSIS MARKET SIZE, BY SPECIES, 2025-2032 (USD MILLION)
• TABLE 261. AFRICA COCCIDIOIDOMYCOSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
• TABLE 262. AFRICA COCCIDIOIDOMYCOSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
• TABLE 263. AFRICA COCCIDIOIDOMYCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 264. AFRICA COCCIDIOIDOMYCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
• TABLE 265. AFRICA COCCIDIOIDOMYCOSIS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 266. AFRICA COCCIDIOIDOMYCOSIS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 267. AFRICA COCCIDIOIDOMYCOSIS MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
• TABLE 268. AFRICA COCCIDIOIDOMYCOSIS MARKET SIZE, BY PATIENT TYPE, 2025-2032 (USD MILLION)
• TABLE 269. ASIA-PACIFIC COCCIDIOIDOMYCOSIS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 270. ASIA-PACIFIC COCCIDIOIDOMYCOSIS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 271. ASIA-PACIFIC COCCIDIOIDOMYCOSIS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
• TABLE 272. ASIA-PACIFIC COCCIDIOIDOMYCOSIS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
• TABLE 273. ASIA-PACIFIC COCCIDIOIDOMYCOSIS MARKET SIZE, BY AZOLES, 2018-2024 (USD MILLION)
• TABLE 274. ASIA-PACIFIC COCCIDIOIDOMYCOSIS MARKET SIZE, BY AZOLES, 2025-2032 (USD MILLION)
• TABLE 275. ASIA-PACIFIC COCCIDIOIDOMYCOSIS MARKET SIZE, BY INFECTION TYPE, 2018-2024 (USD MILLION)
• TABLE 276. ASIA-PACIFIC COCCIDIOIDOMYCOSIS MARKET SIZE, BY INFECTION TYPE, 2025-2032 (USD MILLION)
• TABLE 277. ASIA-PACIFIC COCCIDIOIDOMYCOSIS MARKET SIZE, BY SPECIES, 2018-2024 (USD MILLION)
• TABLE 278. ASIA-PACIFIC COCCIDIOIDOMYCOSIS MARKET SIZE, BY SPECIES, 2025-2032 (USD MILLION)
• TABLE 279. ASIA-PACIFIC COCCIDIOIDOMYCOSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
• TABLE 280. ASIA-PACIFIC COCCIDIOIDOMYCOSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
• TABLE 281. ASIA-PACIFIC COCCIDIOIDOMYCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 282. ASIA-PACIFIC COCCIDIOIDOMYCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
• TABLE 283. ASIA-PACIFIC COCCIDIOIDOMYCOSIS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 284. ASIA-PACIFIC COCCIDIOIDOMYCOSIS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 285. ASIA-PACIFIC COCCIDIOIDOMYCOSIS MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
• TABLE 286. ASIA-PACIFIC COCCIDIOIDOMYCOSIS MARKET SIZE, BY PATIENT TYPE, 2025-2032 (USD MILLION)
• TABLE 287. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 288. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 289. ASEAN COCCIDIOIDOMYCOSIS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 290. ASEAN COCCIDIOIDOMYCOSIS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 291. ASEAN COCCIDIOIDOMYCOSIS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
• TABLE 292. ASEAN COCCIDIOIDOMYCOSIS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
• TABLE 293. ASEAN COCCIDIOIDOMYCOSIS MARKET SIZE, BY AZOLES, 2018-2024 (USD MILLION)
• TABLE 294. ASEAN COCCIDIOIDOMYCOSIS MARKET SIZE, BY AZOLES, 2025-2032 (USD MILLION)
• TABLE 295. ASEAN COCCIDIOIDOMYCOSIS MARKET SIZE, BY INFECTION TYPE, 2018-2024 (USD MILLION)
• TABLE 296. ASEAN COCCIDIOIDOMYCOSIS MARKET SIZE, BY INFECTION TYPE, 2025-2032 (USD MILLION)
• TABLE 297. ASEAN COCCIDIOIDOMYCOSIS MARKET SIZE, BY SPECIES, 2018-2024 (USD MILLION)
• TABLE 298. ASEAN COCCIDIOIDOMYCOSIS MARKET SIZE, BY SPECIES, 2025-2032 (USD MILLION)
• TABLE 299. ASEAN COCCIDIOIDOMYCOSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
• TABLE 300. ASEAN COCCIDIOIDOMYCOSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
• TABLE 301. ASEAN COCCIDIOIDOMYCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 302. ASEAN COCCIDIOIDOMYCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
• TABLE 303. ASEAN COCCIDIOIDOMYCOSIS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 304. ASEAN COCCIDIOIDOMYCOSIS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 305. ASEAN COCCIDIOIDOMYCOSIS MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
• TABLE 306. ASEAN COCCIDIOIDOMYCOSIS MARKET SIZE, BY PATIENT TYPE, 2025-2032 (USD MILLION)
• TABLE 307. GCC COCCIDIOIDOMYCOSIS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 308. GCC COCCIDIOIDOMYCOSIS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 309. GCC COCCIDIOIDOMYCOSIS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
• TABLE 310. GCC COCCIDIOIDOMYCOSIS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
• TABLE 311. GCC COCCIDIOIDOMYCOSIS MARKET SIZE, BY AZOLES, 2018-2024 (USD MILLION)
• TABLE 312. GCC COCCIDIOIDOMYCOSIS MARKET SIZE, BY AZOLES, 2025-2032 (USD MILLION)
• TABLE 313. GCC COCCIDIOIDOMYCOSIS MARKET SIZE, BY INFECTION TYPE, 2018-2024 (USD MILLION)
• TABLE 314. GCC COCCIDIOIDOMYCOSIS MARKET SIZE, BY INFECTION TYPE, 2025-2032 (USD MILLION)
• TABLE 315. GCC COCCIDIOIDOMYCOSIS MARKET SIZE, BY SPECIES, 2018-2024 (USD MILLION)
• TABLE 316. GCC COCCIDIOIDOMYCOSIS MARKET SIZE, BY SPECIES, 2025-2032 (USD MILLION)
• TABLE 317. GCC COCCIDIOIDOMYCOSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
• TABLE 318. GCC COCCIDIOIDOMYCOSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
• TABLE 319. GCC COCCIDIOIDOMYCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 320. GCC COCCIDIOIDOMYCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
• TABLE 321. GCC COCCIDIOIDOMYCOSIS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 322. GCC COCCIDIOIDOMYCOSIS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 323. GCC COCCIDIOIDOMYCOSIS MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
• TABLE 324. GCC COCCIDIOIDOMYCOSIS MARKET SIZE, BY PATIENT TYPE, 2025-2032 (USD MILLION)
• TABLE 325. EUROPEAN UNION COCCIDIOIDOMYCOSIS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 326. EUROPEAN UNION COCCIDIOIDOMYCOSIS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 327. EUROPEAN UNION COCCIDIOIDOMYCOSIS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
• TABLE 328. EUROPEAN UNION COCCIDIOIDOMYCOSIS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
• TABLE 329. EUROPEAN UNION COCCIDIOIDOMYCOSIS MARKET SIZE, BY AZOLES, 2018-2024 (USD MILLION)
• TABLE 330. EUROPEAN UNION COCCIDIOIDOMYCOSIS MARKET SIZE, BY AZOLES, 2025-2032 (USD MILLION)
• TABLE 331. EUROPEAN UNION COCCIDIOIDOMYCOSIS MARKET SIZE, BY INFECTION TYPE, 2018-2024 (USD MILLION)
• TABLE 332. EUROPEAN UNION COCCIDIOIDOMYCOSIS MARKET SIZE, BY INFECTION TYPE, 2025-2032 (USD MILLION)
• TABLE 333. EUROPEAN UNION COCCIDIOIDOMYCOSIS MARKET SIZE, BY SPECIES, 2018-2024 (USD MILLION)
• TABLE 334. EUROPEAN UNION COCCIDIOIDOMYCOSIS MARKET SIZE, BY SPECIES, 2025-2032 (USD MILLION)
• TABLE 335. EUROPEAN UNION COCCIDIOIDOMYCOSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
• TABLE 336. EUROPEAN UNION COCCIDIOIDOMYCOSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
• TABLE 337. EUROPEAN UNION COCCIDIOIDOMYCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 338. EUROPEAN UNION COCCIDIOIDOMYCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
• TABLE 339. EUROPEAN UNION COCCIDIOIDOMYCOSI